• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Decision Support and Centralized Pharmacy Consultation for Nirmatrelvir-Ritonavir Prescribing in an Academic Health System-a Model to Promote Drug Access and Reduce Provider Burden.

作者信息

Millstein Jeffrey H, Asch David A, Hamilton Keith, Adusumalli Srinath, Kasbekar Nishaminy, Ahya Vivek, Al-Ramahi Nida

机构信息

Penn Medicine, Philadelphia, PA, USA.

John Morgan Professor of Medicine, Perelman School of Medicine, Philadelphia, PA, USA.

出版信息

J Gen Intern Med. 2022 Nov;37(15):4028-4031. doi: 10.1007/s11606-022-07752-6. Epub 2022 Aug 3.

DOI:10.1007/s11606-022-07752-6
PMID:35922709
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9362507/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c64/9640514/da7eda4ff838/11606_2022_7752_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c64/9640514/2427b5e3802c/11606_2022_7752_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c64/9640514/da7eda4ff838/11606_2022_7752_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c64/9640514/2427b5e3802c/11606_2022_7752_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c64/9640514/da7eda4ff838/11606_2022_7752_Fig2_HTML.jpg

相似文献

1
Decision Support and Centralized Pharmacy Consultation for Nirmatrelvir-Ritonavir Prescribing in an Academic Health System-a Model to Promote Drug Access and Reduce Provider Burden.学术医疗系统中用于开具奈玛特韦-利托那韦处方的决策支持与集中药房咨询——促进药物可及性并减轻医疗服务提供者负担的模式
J Gen Intern Med. 2022 Nov;37(15):4028-4031. doi: 10.1007/s11606-022-07752-6. Epub 2022 Aug 3.
2
Analyzing the costs of developing and operating an integrated health-system specialty pharmacy: The case of a centralized insurance navigation process for specialty clinic patients.分析开发和运营一体化医疗系统专科药房的成本：以专科诊所患者集中保险导航流程为例。
Am J Health Syst Pharm. 2021 May 24;78(11):982-988. doi: 10.1093/ajhp/zxab083.
3
Pharmaceutical consultations in community pharmacies: utility of the Roter Interaction Analysis System to study pharmacist-patient communication.社区药房的药学咨询：运用罗特互动分析系统研究药剂师与患者的沟通情况
Int J Pharm Pract. 2010 Jun;18(3):141-8.
4
Implementation and quality assessment of a pharmacy services call center for outpatient pharmacies and specialty pharmacy services in an academic health system.学术健康系统中门诊药房和专科药房服务的药学服务呼叫中心的实施与质量评估
Am J Health Syst Pharm. 2018 May 15;75(10):633-641. doi: 10.2146/ajhp170319. Epub 2018 Apr 2.
5
Centralization and automation of non-toxic drug reconstitution in the pharmacy: a strengths, weaknesses, opportunities, and threats analysis.
Int J Pharm Pract. 2024 Feb 15;32(1):97-99. doi: 10.1093/ijpp/riad070.
6
Access to pharmacies and pharmacy services in New York City, Los Angeles, Chicago, and Houston, 2015-2020.2015-2020 年纽约市、洛杉矶、芝加哥和休斯顿的药房和药学服务获取情况。
J Am Pharm Assoc (2003). 2021 Nov-Dec;61(6):e32-e41. doi: 10.1016/j.japh.2021.07.009. Epub 2021 Jul 19.
7
Comparison of provider satisfaction with specialty pharmacy services in integrated health-system and external practice models: A multisite survey.综合医疗系统和外部实践模式下的专业药房服务提供者满意度比较：一项多站点调查。
Am J Health Syst Pharm. 2021 May 24;78(11):962-971. doi: 10.1093/ajhp/zxab079.
8
[Centralized analysis of pharmaceutically prepared medicines].[药物制剂的集中分析]
Sven Farm Tidskr. 1954 Nov 20;58(32):781-4.
9
Analysis of prior authorization success and timeliness at a community-based specialty care pharmacy.社区专科护理药房的事先授权成功率和及时性分析。
J Am Pharm Assoc (2003). 2021 Jul-Aug;61(4S):S173-S177. doi: 10.1016/j.japh.2021.01.001. Epub 2021 Feb 19.
10
Federal and State Pharmacy Regulations and Dispensing Barriers to Buprenorphine Access at Retail Pharmacies in the US.美国联邦和州的药房法规以及零售药房获取丁丙诺啡的配药障碍。
JAMA Health Forum. 2022 Aug 5;3(8):e222839. doi: 10.1001/jamahealthforum.2022.2839.

引用本文的文献

1
Opportunities and challenges associated with the launch of nirmatrelvir/ritonavir (Paxlovid) in British Columbia during the COVID-19 pandemic: A qualitative study to explore community pharmacists' perspectives.在新冠疫情期间于不列颠哥伦比亚省推出奈玛特韦/利托那韦（帕罗韦德）所带来的机遇与挑战：一项探索社区药剂师观点的定性研究
Can Pharm J (Ott). 2024 Nov 15;158(1):55-65. doi: 10.1177/17151635241288577. eCollection 2025 Jan-Feb.
2
Mismanagement of SARS-CoV-2 Infection Pre Hospitalisation during the Omicron Era: Antibiotics and Steroids Instead of Early Antivirals.奥密克戎时代下，对 SARS-CoV-2 感染住院前管理的失误：抗生素和类固醇，而非早期抗病毒药物。
Viruses. 2024 Jun 22;16(7):1005. doi: 10.3390/v16071005.
3
The Penn Medicine COVID-19 Therapeutics Committee-Reflections on a Model for Rapid Evidence Review and Dynamic Practice Recommendations During a Public Health Emergency.
宾夕法尼亚大学医学部新冠治疗委员会——关于公共卫生紧急事件期间快速证据审查及动态实践建议模式的思考
Open Forum Infect Dis. 2023 Aug 9;10(8):ofad428. doi: 10.1093/ofid/ofad428. eCollection 2023 Aug.
4
Nirmatrelvir plus ritonavir in COVID-19: a profile of its use.奈玛特韦片/利托那韦片用于治疗新型冠状病毒肺炎：用药概述
Drugs Ther Perspect. 2023;39(2):41-47. doi: 10.1007/s40267-022-00971-1. Epub 2022 Dec 6.